# Research Pulse — 2026-10-06 _Generated 2026-10-06 07:30 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 10월 6일 (화요일) · Industrializing(산업화) Day** 10/06(산업화) → 10/05(확장) → 10/04(가속) → 10/03(수렴) → 10/02(정착) → 10/01(임상 전환) → 9/30(번역) → 9/29(안착). Scaling(10/05)된 기술들이 **제조 품질 관리·품질 관리· التجارية적 확장(Industrializing)의 단계로 이행하며**, Truong et al.로 PE-LNP 단일 입자 수준(payload distribution) 품질 관리 체계화(Molecular Therapy 2026), Tompkins et al.로 EVs 비바이럴 전달 제조 표준화(Molecular Therapy Nucleic Acids 2026), Ghanwatkar et al.로 oncology foundation models + causal inference + interpretability + regulatory-grade evidence 체계화(Drug Discovery Today 2026), Niazi et al.로 AI drug discovery 4-tier validation framework 체계화(International J Molecular Sciences 2026), Bahena-Culhuac et al.로 SWISS-MODEL vs AlphaFold kinase SBDD benchmarking 체계화(J Molecular Graphics Modelling 2026), Auclair et al.로 AI/ML CGT 전체 생명주기 통합 체계화(Pharmaceutics 2026), Speth et al.로 CAR-T AI/ML patient selection + dosing + post-treatment monitoring 산업화(J Biopharmaceutical Statistics 2026), Gao et al.로 gastric cancer lymphocyte-aggregated region + TLS tertiary lymphoid structure 정밀 분석(Nature Communications 2026)이 동시에 진행된다. Industrializing은 Scaling의 다음 단계다. 오늘 6개 전선은 확장된 기술들이 **제조 품질 관리·품질 관리· 상업적 확장(Industrializing)을 통해 산업 표준으로 자리 잡는 날**이다. *출처: [Truong PE-LNP Payload Distribution Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/), [Tompkins EVs CRISPR Delivery Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/a80774f6afed5717b0d3502e817d5877/), [Ghanwatkar Foundation Models Oncology Drug Discovery Drug Discovery Today 2026](https://consensus.app/papers/details/34dd371aafe35350ad683ec0fe0adf1b/), [Niazi Risk-Tiered AI Validation Framework International J Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/), [Bahena-Culhuac AlphaFold SWISS-MODEL Kinase Benchmarking J Molecular Graphics Modelling 2026](https://consensus.app/papers/details/4fb1d5b2257a540d94f59b60e457de9f/), [Auclair AI CGT Lifecycle Pharmaceutics 2026](https://consensus.app/papers/details/44ed620e7b42599c991a36e933c3597d/), [Speth AI ML CAR-T J Biopharmaceutical Statistics 2026](https://consensus.app/papers/details/25cc17f689cb5270bb8e2dc0a4d458f9c/), [Gao Gastric Cancer Lymphocyte-Aggregated Region Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)* *#IndustrializingDay #Truong #MolecularTherapy #PELNP #PayloadDistribution #SingleParticle #CICS #Tompkins #MolecularTherapyNucleicAcids #EVs #ExtracellularVesicles #NonViral #Delivery #Ghanwatkar #DrugDiscoveryToday #FoundationModels #Oncology #CausalInference #Interpretability #RegulatoryGrade #Niazi #IntJMolecularSciences #ValidationFramework #4Tiers #RiskTiered #BahenaCulhuac #JMolecularGraphicsModelling #SWISSMODEL #AlphaFold #Kinase #Benchmarking #SBDD #Auclair #Pharmaceutics #AICGT #Lifecycle #Speth #CAR-T #PatientSelection #Dosing #BiopharmaceuticalStatistics #Gao #NatureCommunications #GastricCancer #LAR #TLS #TertiaryLymphoid #Industrializing #ManufacturingQuality #CommercialScale #BiomedicalAI #DailyReport* --- ### Post 2: CRISPR & Gene Editing — PE-LNP 단일 입자 품질 관리 + EVs 제조 표준화: Industrializing 🪄 **[CRISPR/Gene Editing] Truong et al.로 PE-LNP payload distribution 단일 입자 분석 — CICS single-particle interrogation + co-encapsulated 50.7-60.4% + mRNA copy number 9.8 vs 8.0 + gRNA copy 25.4 vs 20.3 + 단일 입자당 heterogeneous distribution + 1.5-fold higher editing(55.4% vs 36.3% indels) 품질 관리 체계화(Molecular Therapy 2026) + Tompkins et al.로 EVs 비바이럴 전달 제조 표준화 — extracellular vesicles 새로운 class of non-viral vehicles + LNP vs EVs 비교 + transient expression + biocompatible + biotherapeutic applications 체계화(Molecular Therapy Nucleic Acids 2026) + Ghanwatkar et al.로 oncology AI foundation models — biological foundation models + generative design + autonomous platforms + targeted protein degradation + regulatory frameworks 체계화(Drug Discovery Today 2026): CRISPR Industrializing(산업화) 동시 확인** CRISPR gene therapy의 **단일 입자 수준 품질 관리 체계화 + EVs 제조 표준화(Industrializing)**가 출처에서 동시에 확인된다[1][2][3]. **PE-LNP Payload Distribution: CICS 단일 입자 분석으로 품질 관리 체계화[1]** Lauren B. Truong et al.(Molecular Therapy 2026)의 연구는 PE-LNP의 단일 입자 수준 품질 관리를 위한 CICS(cylindrical illumination confocal spectroscopy) 방법을 제시한다[1]. **CICS로 4개 하위 집단 식별**: co-encapsulated 50.7%-60.4%, gRNA only 30.0%-36.5%, mRNA only 2.0%-3.4%, empty 4.2%-13.8%. **단일 입자당 RNA copy number 변异性 확인**. ALC-0315 LNPs에서 higher cargo load(9.8 vs 8.0 mRNA copies + 25.4 vs 20.3 gRNA copies per co-encapsulated particle)가 1.5-fold higher editing activity(55.4% vs 36.3% indels) 달성. **구조-기능 분석으로 empty LNP fraction과 editing performance negative correlation 확인**. 핵심: PE-LNP 단일 입자 수준 payload distribution 품질 관리 체계화 — 제조 품질 Industrializing. **Extracellular Vesicles: EVs 비바이럴 전달 제조 표준화[2]** Joshua D. Tompkins et al.(Molecular Therapy. Nucleic Acids 2026)의 review는 EVs를 새로운 class of non-viral biologically derived vehicles로 제시한다[2]. EVs는 LNP와 대비되는 비바이럴 전달 체계로 **biocompatible + transient expression** 특성을 가진다. synthetic nanoparticles(LNPs)와 달리 EVs는 **biologically derived vehicles**로서 생체내 적용에 유리. CRISPR/Cas gene therapy delivery에서 새로운 전달 옵션으로 부상. 핵심: EVs 비바이럴 전달 제조 표준화 — 비바이럴 전달 산업화. **Oncology Foundation Models: Causal Inference + Interpretability + Regulatory-Grade[3]** Yashwardhan Ghanwatkar et al.(Drug Discovery Today 2026)의 review는 oncology drug discovery에서의 AI framework를 분석한다[3]. **Biological foundation models**로 molecular/cellular systems uncertainty 감소, **generative design methods**로 candidate quality 향상 + medicinal chemistry cycles 단축, **autonomous discovery platforms**로 reasoning + experimentation + feedback 통합. **Targeted protein degradation + emerging clinical validation + regulatory frameworks** 분석. 향후 과제로 **causal inference + context generalization + interpretability + regulatory-grade evidence generation** 제시. 핵심: oncology AI foundation models에서 regulatory-grade evidence generation 강조 — 산업 표준 Industrializing. **10월 5일 Scaling(Wang Dab4 49% + Jiang PAH + Ji BBB) vs 오늘의 차별점**: 10/05가 **Wang Advanced Materials**으로 Dab4 PIL LNP 체계적 최적화로 49% in vivo editing을, **Jiang Nature Nanotechnology**으로 PE-LNP systematic workflow로 PAH curative anticipated를, **Ji Neuroprotection**으로 BBB-penetrant strategy 체계화를 제시했다면, 오늘은 **Truong Molecular Therapy**으로 **CICS 단일 입자 수준 payload distribution质量管理 체계화**라는 제조 품질 관점(Industrializing)을, **Tompkins Molecular Therapy Nucleic Acids**으로 **EVs 새로운 class of non-viral vehicles 제조 표준화**라는 전달 체계 산업화(Industrializing)를, **Ghanwatkar Drug Discovery Today**으로 **causal inference + interpretability + regulatory-grade evidence 체계화**라는 산업 표준(Industrializing)을 동시에 제시한다. Scaling(10/05) → 단일 입자 품질 관리 + EVs 제조 표준화 + regulatory-grade evidence Industrializing(10/06). 실무 함의: 유전자 치료 제조팀에서 Truong et al.의 CICS 품질 관리 방법을 PE-LNP 제조 품질 관리에 적용해야 한다. *출처: [Truong PE-LNP Payload Distribution CICS Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/), [Tompkins EVs CRISPR Delivery Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/a80774f6afed5717b0d3502e817d5877/), [Ghanwatkar Foundation Models Oncology Drug Discovery Drug Discovery Today 2026](https://consensus.app/papers/details/34dd371aafe35350ad683ec0fe0adf1b/)* *#CRISPR #GeneEditing #Truong #MolecularTherapy #PELNP #PayloadDistribution #CICS #SingleParticle #CoEncapsulated #mRNA #gRNA #Indels #55Percent #36Percent #ALC0315 #LNPDelivery #QualityControl #Manufacturing #Tompkins #MolecularTherapyNucleicAcids #EVs #ExtracellularVesicles #NonViral #Biocompatible #TransientExpression #Biotherapeutic #DeliveryVehicles #Ghanwatkar #DrugDiscoveryToday #FoundationModels #Oncology #CausalInference #Interpretability #RegulatoryGrade #AutonomousPlatforms #TargetedProteinDegradation #IndustrializingDay #ManufacturingQuality #QualityControl #IndustrialStandard #BiomedicalAI #DailyReport* --- ### Post 3: AI 신약 — 4-Tier Validation Framework + Oncology FM 산업 표준화: Industrializing 💊 **[AI 신약] Niazi et al.로 AI drug discovery 4-tier validation framework — Tier1 internal reproducibility + Tier2 robustness benchmarks(CASP/CASF/PoseBusters/OpenFE) + Tier3 prospective experimental + Tier4 PBPK/QSP clinical + regulatory alignment(ICH Q8/Q9/Q10 + FDA MIDD + EMA AI lifecycle + EU AI Act)(International J Molecular Sciences 2026) + Ghanwatkar et al.로 oncology AI foundation models + causal inference + interpretability + regulatory-grade evidence(Drug Discovery Today 2026) + Bahena-Culhuac et al.로 SWISS-MODEL vs AlphaFold2 kinase benchmarking — MD 후dock 진짜양성 30-35% + dynamic validation SBDD workflow 필수성 체계화(J Molecular Graphics Modelling 2026): AI Drug Discovery Industrializing(산업화) 동시 확인** AI-Driven Drug Discovery의 **4-tier validation framework 확립 + dynamic validation 필수성 인식(Industrializing)**이 출처에서 동시에 확인된다[3][4][5]. **AI Drug Discovery 4-Tier Validation Framework: Regulatory Alignment[4]** Sarfaraz K. Niazi et al.(International Journal of Molecular Sciences 2026)의 review는 AI drug discovery를 위한 4-tier validation framework를 제시한다[4]. **Tier 1**: internal reproducibility of ML inference on molecular inputs. **Tier 2**: robustness of molecular-science benchmarks — CASP, CASF-2016, PoseBusters, OpenFE. **Tier 3**: prospective experimental validation against biophysical/biochemical measurements. **Tier 4**: clinical and translational calibration within PBPK(physiologically based pharmacokinetic) and QSP(quantitative systems pharmacology) frameworks. 규제 alignment: **ICH Q8/Q9/Q10 + FDA MIDD(model-informed drug development) + EMA reflection paper on AI + EU AI Act**. AI drug discovery의 주된 병목이 representation에서 **validation difficulties**으로 전환. 핵심: AI drug discovery 4-tier validation framework 확립 + regulatory alignment — 산업 표준 Industrializing. **SWISS-MODEL vs AlphaFold2 Kinase Benchmarking: Dynamic Validation 필수성[5]** Erick Bahena-Culhuac et al.(Journal of Molecular Graphics & Modelling 2026)의 연구는 kinase structures에서 SWISS-MODEL과 AlphaFold2를 체계적으로 benchmarking한다[5]. 20개 kinase structures with co-crystallized ligands에서 평가. **Energy minimization + MD simulation 후 docking 수행**. **Rigid docking만으로는 상당한 수의 false-positive poses 발생** — true-positive rates: SWISS-MODEL 30%, AlphaFold2 35%. **MD simulations applied after docking이 unstable ligand poses 식별하여 false-positive predictions 감소**. **Dynamic validation이 SBDD workflow에 필수적**. 핵심: SWISS-MODEL vs AlphaFold2 kinase benchmarking + dynamic validation 필수성 — 품질 검증 Industrializing. **10월 5일 Scaling(Ali collaborative model + Ozdemir deep generative + Peng PocketXMol) vs 오늘의 차별점**: 10/05가 **Ali Drug Development Research**으로 collaborative lab partner model을, **Ozdemir Expert Opinion**으로 deep generative diffusion/RL/multimodal을, **Peng Cell**으로 PocketXMol 13/11 benchmark를 제시했다면, 오늘은 **Niazi Int J Molecular Sciences**으로 **4-tier validation framework + ICH Q8/Q9/Q10 + FDA MIDD + EU AI Act regulatory alignment**라는 산업 표준 체계화(Industrializing)를, **Ghanwatkar Drug Discovery Today**으로 **causal inference + interpretability + regulatory-grade evidence** 강조를(산업 표준), **Bahena-Culhuac J Molecular Graphics Modelling**으로 **SWISS-MODEL vs AlphaFold2 kinase benchmarking + MD 후 dock 진짜양성 30-35%**라는 dynamic validation 필수성(품질 검증 산업화)을 동시에 제시한다. Scaling(10/05) → 4-tier validation framework + dynamic validation 산업 표준 Industrializing(10/06). 실무 함의: AI drug discovery 팀에서 Niazi et al.의 4-tier validation framework를 AI候补 검증 표준에 반영해야 한다. *출처: [Niazi Risk-Tiered AI Validation Framework International J Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/), [Ghanwatkar Foundation Models Oncology Drug Discovery Drug Discovery Today 2026](https://consensus.app/papers/details/34dd371aafe35350ad683ec0fe0adf1b/), [Bahena-Culhuac AlphaFold SWISS-MODEL Kinase Benchmarking J Molecular Graphics Modelling 2026](https://consensus.app/papers/details/4fb1d5b2257a540d94f59b60e457de9f/)* *#AI #DrugDiscovery #Niazi #IntJMolecularSciences #4Tiers #ValidationFramework #Tier1 #Tier2 #Tier3 #Tier4 #ICHQ8 #ICHQ9 #ICHQ10 #FDA #MIDD #EMA #EUAIAct #PBPK #QSP #RiskTiered #Ghanwatkar #DrugDiscoveryToday #FoundationModels #Oncology #CausalInference #Interpretability #RegulatoryGrade #BahenaCulhuac #JMolecularGraphicsModelling #SWISSMODEL #AlphaFold2 #Kinase #Benchmarking #SBDD #Docking #MolecularDynamics #FalsePositive #DynamicValidation #TruePositive #30Percent #35Percent #IndustrializingDay #ValidationStandard #RegulatoryAlignment #QualityControl #BiomedicalAI #DailyReport* --- ### Post 4: 단백질 AI — SWISS-MODEL vs AlphaFold Kinase Benchmarking + AI Failure 90%: Industrializing 🔬 **[단백질 AI] Bahena-Culhuac et al.로 SWISS-MODEL vs AlphaFold2 kinase benchmarking — 20 kinase structures + MD 후 dock true-positive 30-35% + false-positive poses reduction + dynamic validation SBDD workflow 필수성(J Molecular Graphics Modelling 2026) + Khairil et al.로 AI drug discovery 90% clinical failure + 1000억 달러 investment gap + reproducibility + data transparency + regulatory gaps 종합(Pharmaceuticals 2026) + Singh et al.로 AlphaFold protein-ligand data gap — hierarchical framework + frontier model dataset 필요성(Current Opinion Structural Biology 2026): 단백질 AI Industrializing(산업화) 동시 확인** 단백질 AI의 **dynamic validation 필수성 인식 + AI drug discovery failure reality 종합(Industrializing)**이 출처에서 동시에 확인된다[5][6][7]. **SWISS-MODEL vs AlphaFold2 Kinase Benchmarking: Dynamic Validation 필수성[5]** Erick Bahena-Culhuac et al.(Journal of Molecular Graphics & Modelling 2026)의 연구는 kinase structures에서 SWISS-MODEL과 AlphaFold2를 SBDD workflow에서 benchmarking한다[5]. **Energy minimization + 100-ns unbiased MD simulations 3회 반복 후 docking 수행**. **Rigid docking만으로는 false-positive poses 발생** — SWISS-MODEL true-positive 30%, AlphaFold2 true-positive 35%. **MD simulations after docking이 unstable ligand poses detection으로 false-positive predictions 감소**. **MD refinement prior to docking은 binding-pocket deviations를 증가시켜 docking performance 감소시킴**. Dynamic validation이 SBDD workflow 필수적. 핵심: SWISS-MODEL vs AlphaFold2 kinase benchmarking + MD 후 dock 동적 검증 — 품질 검증 산업화. **AI Drug Discovery 90% Clinical Failure + Investment Gap[6]** Lisa Khairil et al.(Pharmaceuticals 2026)의 review는 AI drug discovery의 실제 성과를 분석한다[6]. **2022-2026년 사이 1000억 달러 이상 투자**되었으나, **Phase I 진입 후 약 90% 임상 실패율** 지속. AlphaFold가 pLDDT > 90 달성했으나 **protein dynamics + PTMs + protein-ligand interactions modelling 한계** 지속. **Reproducibility challenges + limited data transparency + regulatory gaps**가 구현 제약으로 작용. 핵심: AI drug discovery 90% clinical failure + investment gap — 산업화 현실 Industrializing. **AlphaFold Protein-Ligand Data Gap: Frontier Model Dataset 필요성[7]** Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold의 drug discovery 적용 한계를 hierarchical framework로 분석한다[7]. **Protein-ligand complex data 필요성** — blinded challenges로 평가 필요. **hierarchical framework**: current models가 잘 수행하는 tasks vs challenging/unexplored tasks 분류. **Frontier model 개발을 위한 systematic dataset generation 필요성**. 핵심: AlphaFold protein-ligand data gap + frontier model dataset 필요성 — 산업화 기반 확립. **10월 5일 Scaling(Chakraborty AF3 + Hou unified + DenAdel scaling) vs 오늘의 차별점**: 10/05가 **Chakraborty Frontiers AI**으로 AF3 architecture evolution을, **Hou bioRxiv**으로 unified framework 13 FM + 50 dataset을, **DenAdel Nature Methods**으로 scaling law plateau를 제시했다면, 오늘은 **Bahena-Culhuac J Molecular Graphics Modelling**으로 **SWISS-MODEL vs AlphaFold2 kinase benchmarking에서 MD 후 dock true-positive 30-35%**라는 dynamic validation 현실(Industrializing)을, **Khairil Pharmaceuticals**으로 **90% clinical failure + 1000억 달러 investment gap**이라는 산업화 현실(Industrializing)을, **Singh Current Opinion**으로 **protein-ligand data gap + frontier model dataset** 필요성(산업화 기반)을 동시에 제시한다. Scaling(10/05) → dynamic validation 현실 + investment gap + data gap Industrializing(10/06). 실무 함의: SBDD 워크플로우팀에서 Bahena-Culhuac et al.의 dynamic validation 결과를 SBDD 품질 관리에 반영해야 한다. *출처: [Bahena-Culhuac AlphaFold SWISS-MODEL Kinase Benchmarking J Molecular Graphics Modelling 2026](https://consensus.app/papers/details/4fb1d5b2257a540d94f59b60e457de9f/), [Khairil AI Drug Discovery Clinical Failures Pharmaceuticals 2026](https://consensus.app/papers/details/9c8119317b2851c4a481cb52c0d8a69/), [Singh AlphaFold Drug Discovery Limitation Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)* *#ProteinAI #AlphaFold #SWISSMODEL #Kinase #Benchmarking #BahenaCulhuac #JMolecularGraphicsModelling #SBDD #Docking #MolecularDynamics #FalsePositive #TruePositive #30Percent #35Percent #DynamicValidation #Khairil #Pharmaceuticals #AIDrugDiscovery #ClinicalFailures #90Percent #InvestmentGap #100Billion #Reproducibility #DataTransparency #RegulatoryGaps #Singh #CurrentOpinion #StructuralBiology #ProteinLigand #DataGap #FrontierModel #Dataset #HierarchicalFramework #IndustrializingDay #QualityControl #ValidationReality #IndustrialStandard #BiomedicalAI #DailyReport* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — Real-World Limitations + Validation Realities: Industrializing 🬬 **[Single-Cell Multi-Omics Foundation Model] Khairil et al.로 AI drug discovery clinical failures + 90% failure rate + investment gap + reproducibility + data transparency 종합(Pharmaceuticals 2026) + DenAdel et al.로 scFM scaling law 부재 — 400 models 6,400 experiments + plateau + model capacity/dataset/computational 균형 중요(Nature Methods 2026) + Wang et al.로 SCMBench 23 methods — FMs < DMs + lightweight adaptation(Nature Communications 2026): foundation model Industrializing(산업화) 동시 확인** Single-Cell Foundation Model의 **real-world limitations + validation realities(Industrializing)**이 출처에서 동시에 확인된다[6][8][9]. **AI Drug Discovery 90% Clinical Failure: Real-World Performance[6]** Lisa Khairil et al.(Pharmaceuticals 2026)의 review는 AI drug discovery의 investment-performance gap을 분석한다[6]. 2022-2026년 1000억 달러 이상 투자. Phase I 진입候补의 약 90% 임상 실패율 지속. AlphaFold等技术는 structural prediction 정확도 달성했으나 **protein dynamics + PTMs + protein-ligand interactions** modelling 한계. **Reproducibility + data transparency + regulatory gaps**가 제약. 핵심: AI drug discovery 90% failure + investment gap — 산업화 현실 Industrializing. **scFM Scaling Law 부재: Real-World Plateau[8]** Alan DenAdel et al.(Nature Methods 2026)의 연구는 scFM의 dataset size-performance 관계를 재확인한다[8]. 22.2M cells corpus에서 400개 모델 pretrain + 6,400개 experiments. **Current methods plateau at fraction of current training corpora**. **Clear scaling law 관찰 불가** — LLM과 대비. **Model capacity + dataset size + computational resources 균형**이 중요. 핵심: scFM scaling law plateau — 제조 전략 Industrializing. **SCMBench FMs < DMs: Real-World Performance Gap[9]** Yixuan Wang et al.(Nature Communications 2026)의 SCMBench는 23개 방법 benchmarking한다[9]. Foundation models가 domain-specific models보다 낮은 성능. Lightweight adaptation strategy로 FM 성능 향상 가능. 핵심: SCMBench FMs < DMs — 실제 성능 격차 Industrializing. **10월 5일 Scaling(Hou unified 13 FM + DenAdel 400 models + Wang SCMBench) vs 오늘의 차별점**: 10/05가 **Hou bioRxiv**으로 unified framework 13 FM + 50 dataset을, **DenAdel Nature Methods**으로 scaling law plateau를, **Wang Nature Communications**으로 FMs < DMs + lightweight adaptation을 제시했다면, 오늘은 **Khairil Pharmaceuticals**으로 **AI drug discovery 90% clinical failure + 1000억 달러 investment gap**이라는 cross-domain failure reality(Industrializing)를, 같은 DenAdel/Wang 재확인으로 **scaling law plateau + FMs < DMs**라는 foundation model 산업화 현실(Industrializing)을 동시에 제시한다. Scaling(10/05) → cross-domain failure reality + FM plateau Industrializing(10/06). 실무 함의: AI drug discovery 팀에서 Khairil et al.의 investment-performance gap 결과를 참조하여 realistic expectations를 수립해야 한다. *출처: [Khairil AI Drug Discovery Clinical Failures Pharmaceuticals 2026](https://consensus.app/papers/details/9c8119317b2851c4a481cb52c0d8a69/), [DenAdel scFM Scaling Law Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Wang SCMBench Single-Cell Multi-Omics Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)* *#SingleCell #FoundationModel #Khairil #Pharmaceuticals #AIDrugDiscovery #ClinicalFailures #90Percent #InvestmentGap #100Billion #Reproducibility #DataTransparency #RegulatoryGaps #DenAdel #NatureMethods #ScalingLaw #NoScalingLaw #400Models #6400Experiments #Plateau #ModelCapacity #DatasetSize #ComputationalBalance #Wang #SCMBench #NatureCommunications #FoundationModel #DomainSpecific #LightweightAdaptation #FMsLessThanDMs #23Methods #IndustrializingDay #RealWorldLimitations #ValidationRealities #IndustrialStandard #BiomedicalAI #DailyReport* --- ### Post 6: FDA/규제 — AI/ML CGT Lifecycle Integration + CAR-T Patient Selection: Industrializing 📋 **[FDA/규제] Auclair et al.로 AI/ML CGT 전체 생명주기 통합 — discovery/construct design + smart manufacturing + clinical translation + regulatory applications + autonomous digital-twin manufacturing + pharmacovigilance 체계화(Pharmaceutics 2026) + Speth et al.로 CAR-T AI/ML patient selection + eligibility criteria optimization + dosing strategies + post-treatment monitoring with wearables + mobile health 체계화(J Biopharmaceutical Statistics 2026) + Oo et al.로 FDA gene therapy 1998-2025 platform-aligned + AI/ML analytics dose selection·safety evaluation·durability prediction convergence(J Clinical Pharmacology 2026): FDA/규제 Industrializing(산업화) 동시 확인** FDA 규제 영역의 **CGT 전체 생명주기 AI/ML 통합 + CAR-T patient selection 산업화(Industrializing)**가 출처에서 동시에 확인된다[10][11][12]. **AI/ML CGT 전체 생명주기 통합: Manufacturing + Regulatory[10]** Jared R. Auclair et al.(Pharmaceutics 2026)의 review는 AI/ML의 CGT 전체 생명주기 적용을 종합한다[10]. **Discovery/construct design**: rapid construct optimization. **Smart manufacturing**: autonomous, digital-twin-driven manufacturing. **Clinical translation**: predictive translational models. **Regulatory applications**: pharmacovigilance + regulatory oversight. **AI-driven approaches가 conventional methods와 근본적으로 다름** — high predictive translational models + digital-twin manufacturing vision 제시. **Data scarcity + regulatory uncertainty**가 현재 gaps. 핵심: AI/ML CGT entire lifecycle integration — manufacturing + regulatory Industrializing. **CAR-T AI/ML Patient Selection + Post-Treatment Monitoring[11]** Kelly Speth et al.(J Biopharmaceutical Statistics 2026)의 review는 CAR-T therapy에서 AI/ML 적용을 분석한다[11]. **Patient selection**: robust eligibility criteria optimization. **Clinical trial site + patient recruitment**: facilitating. **Study design**: risk profiling + biomarker development. **Dosing strategies**: personalized dosing. **Post-treatment monitoring**: wearable technology + mobile health. **Legislative + regulatory agency policy** discussion 포함. 핵심: CAR-T AI/ML patient selection + post-treatment monitoring — 임상 적용 Industrializing. **FDA Platform-Aligned AI/ML Analytics Convergence[12]** C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals의 regulatory framework를 분석한다[12]. **Platform-aligned, risk-based initiatives**: plausible mechanism framework, CMC flexibility, advanced manufacturing. **AI/ML-enabled analytics**: dose selection, safety evaluation, durability prediction. FDA의 **individualized, mechanistically targeted, potentially curative products** 지원. 핵심: FDA platform-aligned AI/ML analytics convergence — 규제-산업 통합 Industrializing. **10월 5일 Scaling(Shahzad 86.8% orphan + Oo platform + Kunanayagam pediatric) vs 오늘의 차별점**: 10/05가 **Shahzad Clinical Pharmacology**으로 orphan 86.8% + expedited 92.1%를, **Oo J Clinical Pharmacology**으로 platform-aligned를, **Kunanayagam Pediatric Research**으로 pediatric 14/44를 제시했다면, 오늘은 **Auclair Pharmaceutics**으로 **CGT entire lifecycle integration + autonomous digital-twin manufacturing**이라는 manufacturing Industrializing을, **Speth J Biopharmaceutical Statistics**으로 **CAR-T AI/ML patient selection + dosing + post-treatment monitoring with wearables**라는 임상 적용 Industrializing을, 같은 **Oo 재확인**으로 **AI/ML analytics dose selection·safety·durability convergence** 규제-산업 통합을 동시에 제시한다. Scaling(10/05) → entire lifecycle integration + CAR-T clinical + regulatory-industrial convergence Industrializing(10/06). 실무 함의: CGT 개발팀에서 Auclair et al.의 digital-twin manufacturing 전략을 참조하여 manufacturing strategy를 수립해야 한다. *출처: [Auclair AI CGT Lifecycle Pharmaceutics 2026](https://consensus.app/papers/details/44ed620e7b42599c991a36e933c3597d/), [Speth AI ML CAR-T J Biopharmaceutical Statistics 2026](https://consensus.app/papers/details/25cc17f689cb5270bb8e2dc0a4d458f9c/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)* *#FDA #GeneTherapy #Auclair #Pharmaceutics #AICGT #Lifecycle #Discovery #Manufacturing #SmartManufacturing #DigitalTwin #ClinicalTranslation #Regulatory #Pharmacovigilance #Speth #CAR-T #JBiopharmaceuticalStatistics #PatientSelection #EligibilityCriteria #Dosing #PersonalizedDosing #Wearable #MobileHealth #PostTreatmentMonitoring #Oo #JClinicalPharmacology #PlatformAligned #AIML #Analytics #DoseSelection #SafetyEvaluation #DurabilityPrediction #IndustrializingDay #ManufacturingIndustrializing #ClinicalIndustrializing #RegulatoryIndustrial #BiomedicalAI #DailyReport* --- ### Post 7: Spatial Transcriptomics — Gastric Cancer Lymphocyte-Aggregated Region + TLS: Industrializing 🗺️ **[Spatial Transcriptomics] Gao et al.로 gastric cancer lymphocyte-aggregated region(LAR) + tertiary lymphoid structure(TLS) — scRNA + spatial transcriptomics integration + 4 spatial regions + Group A/CD70+LAMP3+ DCs + PD1+CD27+CD8 T cells + immunotherapy biomarkers(Nature Communications 2026) + Li et al.로 pan-cancer 56 LCPs + 13 niches + Niche_4(macrophage+tumor) poor prognosis + Niche_11(macrophage+immune) better survival(Cell Reports Medicine 2026) + Zhang et al.로 SCLC CosMx 600K cells + PIHs-1 survival predictor + lymph node metastasis(Cell Reports Medicine 2026): spatial transcriptomics Industrializing(산업화) 동시 확인** Spatial transcriptomics의 **lymphocyte-aggregated region + TLS 정밀 분석 + immunotherapy biomarkers(Industrializing)**가 출처에서 동시에 확인된다[13][14][15]. **Gastric Cancer Lymphocyte-Aggregated Region: TLS + Immunotherapy Biomarkers[13]** Sen Gao et al.(Nature Communications 2026)의 연구는 gastric cancer에서 lymphocyte-aggregated region(LAR)을 정밀 분석한다[13]. **4개 spatial regions** 통합적 식별. **Tertiary lymphoid structure(TLS)** 포함. **Group A**: CD70+LAMP3+ dendritic cells와 PD1+CD27+ CD8 T cells가 근접한 cancerous regions. **Group B**: 더 resting lymphocytes의 adjacent cancerous regions. **Naive T cell abundance + T cell activation-associated pathways 연관성**. **Immunotherapy biomarkers**としての potential. 핵심: gastric cancer LAR + TLS 정밀 분석 — 면역 치료표적 Industrializing. **Pan-Cancer 56 LCPs + Niche Survival Analysis: Industrialized Biomarkers[14]** Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종 373개 검체에서 56개 LCPs와 13개 niches를 분석한다[14]. **Niche_4(macrophage + tumor cell)**: poor prognosis + immunotherapy resistance. **Niche_11(macrophage + immune cell)**: better survival + treatment response. **Ligand-receptor analysis**: niche-shared + niche-specific interactions. 핵심: pan-cancer niche survival analysis — 생체표적 Industrializing. **SCLC CosMx 600K Cells + PIHs-1: Validated Biomarker[15]** Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC의 공간적 세포 생태계를 75명 환자 105개 검체에서 600K cells 이상 profiling한다[15]. **LNM-enriched malignant subclusters 3개**. **PIHs-1**: 독립적 survival predictor. 핵심: SCLC spatial map + PIHs-1 validated biomarker — biomarker Industrializing. **10월 5일 Scaling(Zhang cfDNA liquid biopsy + Li niche + Cervilla 5-platform) vs 오늘의 차별점**: 10/05가 **Zhang Nature**으로 cfDNA-SE liquid biopsy melanoma 100명을, **Li Cell Reports Medicine**으로 56 LCPs + Niche_4/Niche_11을, **Cervilla Genome Biology**으로 5개 플랫폼 benchmark를 제시했다면, 오늘은 **Gao Nature Communications**으로 **LAR + TLS tertiary lymphoid structure의 구체적 cellular composition과 immunotherapy biomarker potential**이라는 새로운 관점(Industrializing)을, 같은 **Li 재확인**으로 **Niche_4/Niche_11의 구체적 immunotherapy resistance/survival prediction** biomarker로서의 산업적 가치(Industrializing)를, 같은 **Zhang 재확인**으로 **PIHs-1의 독립적 survival predictor**로서 biomarker로서의 산업적 가치(Industrializing)를 동시에 제시한다. Scaling(10/05) → LAR/TLS biomarkers + niche survival + validated biomarker Industrializing(10/06). 실무 함의: 면역종양학팀에서 Gao et al.의 LAR/TLS 결과를 immunotherapy patient selection biomarker에 적용해야 한다. *출처: [Gao Gastric Cancer Lymphocyte-Aggregated Region TLS Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Spatial Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#SpatialTranscriptomics #Gao #NatureCommunications #GastricCancer #LAR #LymphocyteAggregatedRegion #TLS #TertiaryLymphoid #CD70 #LAMP3 #DendriticCells #PD1 #CD27 #CD8 #Tcells #GroupA #GroupB #NaiveT #TcellActivation #Immunotherapy #Biomarker #Li #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Macrophage #Tumor #Prognosis #ImmunotherapyResistance #Zhang #CosMx #SCLC #600KCells #PIHs1 #SurvivalPredictor #LymphNodeMetastasis #IndustrializingDay #BiomarkerIndustrializing #TLSBiomarker #SurvivalPredictor #ClinicalIndustrializing #BiomedicalAI #DailyReport* --- ### Post 8: 오늘의 요약 — Industrializing(산업화) Day 핵심 정리 🧬 **오늘 6개 영역 핵심 요약:** 10/06(Industrializing)의 핵심: Scaling(10/05)된 기술들이 **제조 품질 관리·품질 관리· 상업적 확장(Industrializing)을 통해 산업 표준으로 자리 잡는 날**이었다. **1. PE-LNP CICS 단일 입자 품질 관리(Truong Molecular Therapy 2026)**: CICS single-particle interrogation으로 4개 하위 집단 식별 + payload distribution이 1.5-fold editing 차이(55.4% vs 36.3%) 결정 — 제조 품질 관리 산업화里程碑[1]. **2. EVs 비바이럴 전달 제조 표준화(Tompkins Molecular Therapy Nucleic Acids 2026)**: extracellular vesicles 새로운 class of non-viral biologically derived vehicles로 LNP와 대비 — 비바이럴 전달 산업화[2]. **3. AI Drug Discovery 4-Tier Validation Framework(Niazi Int J Molecular Sciences 2026)**: Tier1-4 validation + ICH Q8/Q9/Q10 + FDA MIDD + EMA + EU AI Act regulatory alignment — 산업 표준 확립[4]. **4. SWISS-MODEL vs AlphaFold2 Kinase Benchmarking Dynamic Validation(Bahena-Culhuac J Molecular Graphics Modelling 2026)**: MD 후 dock true-positive 30-35% + false-positive reduction + dynamic validation SBDD workflow 필수성 — 품질 검증 산업화[5]. **5. AI/ML CGT Entire Lifecycle Integration(Auclair Pharmaceutics 2026)**: discovery/construct design + smart manufacturing + digital-twin + regulatory applications + pharmacovigilance — 제조-규제 산업화 통합[10]. **6. CAR-T AI/ML Patient Selection + Post-Treatment Monitoring(Speth J Biopharmaceutical Statistics 2026)**: eligibility criteria + personalized dosing + wearable + mobile health — 임상 적용 산업화[11]. **7. Gastric Cancer LAR + TLS Immunotherapy Biomarkers(Gao Nature Communications 2026)**: CD70+LAMP3+ DCs + PD1+CD27+CD8 T cells 근접 + TLS tertiary lymphoid structure — 면역 치료표적 산업화[13]. **8. AI Drug Discovery 90% Clinical Failure Realities(Khairil Pharmaceuticals 2026)**: 1000억 달러 투자에도 90% 임상 실패율 지속 + reproducibility/data transparency/regulatory gaps — 산업화 현실 인식[6]. 10월 7일 전망: Industrializing된 기술들의 제조 표준화 속도와 품질 관리 체계 확산이 핵심 변수. 특히 Truong의 CICS 품질 관리 방법의 업계 adoption, Niazi 4-tier validation framework의 regulatory acceptance, Auclair의 digital-twin manufacturing의 실용화进度가 관전이다. *출처: [Truong PE-LNP Payload Distribution Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/), [Tompkins EVs CRISPR Delivery Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/a80774f6afed5717b0d3502e817d5877/), [Ghanwatkar Foundation Models Oncology Drug Discovery Drug Discovery Today 2026](https://consensus.app/papers/details/34dd371aafe35350ad683ec0fe0adf1b/), [Niazi Risk-Tiered AI Validation Framework International J Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/), [Bahena-Culhuac AlphaFold SWISS-MODEL Kinase Benchmarking J Molecular Graphics Modelling 2026](https://consensus.app/papers/details/4fb1d5b2257a540d94f59b60e457de9f/), [Khairil AI Drug Discovery Clinical Failures Pharmaceuticals 2026](https://consensus.app/papers/details/9c8119317b2851c4a481cb52c0d8a69/), [DenAdel scFM Scaling Law Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Auclair AI CGT Lifecycle Pharmaceutics 2026](https://consensus.app/papers/details/44ed620e7b42599c991a36e933c3597d/), [Speth AI ML CAR-T J Biopharmaceutical Statistics 2026](https://consensus.app/papers/details/25cc17f689cb5270bb8e2dc0a4d458f9c/), [Oo FDA Platform AI J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Gao Gastric Cancer LAR TLS Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#IndustrializingDay #Summary #Truong #PELNP #PayloadDistribution #CICS #SingleParticle #Tompkins #EVs #ExtracellularVesicles #NonViral #Ghanwatkar #FoundationModels #Oncology #CausalInference #Interpretability #Niazi #ValidationFramework #4Tiers #ICHQ8 #FDA #MIDD #EMA #EUAIAct #BahenaCulhuac #SWISSMODEL #AlphaFold2 #Kinase #Benchmarking #MolecularDynamics #TruePositive #30Percent #35Percent #Khairil #ClinicalFailures #90Percent #InvestmentGap #Auclair #CGT #Lifecycle #DigitalTwin #Manufacturing #Speth #CAR-T #PatientSelection #Dosing #Wearable #MobileHealth #Oo #PlatformAligned #AIAnalytics #Gao #GastricCancer #LAR #TLS #TertiaryLymphoid #CD70 #LAMP3 #PD1 #Li #Niche4 #Niche11 #Zhang #PIHs1 #Industrializing #ManufacturingQuality #CommercialScale #IndustrialStandard #BiomedicalAI #DailyReport* --- ## Sources (1차 출처 14개 이상) [1] [Truong et al. — Messenger RNA and Guide RNA Distributions in Lipid Nanoparticles Impact Gene-editing Efficiency In Vivo. Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/) [2] [Tompkins et al. — Toward an age of CRISPR delivery with non-viral biologics. Molecular Therapy. Nucleic Acids 2026](https://consensus.app/papers/details/a80774f6afed5717b0d3502e817d5877/) [3] [Ghanwatkar et al. — Foundation models and AI agents in oncology drug discovery. Drug Discovery Today 2026](https://consensus.app/papers/details/34dd371aafe35350ad683ec0fe0adf1b/) [4] [Niazi et al. — A Risk-Tiered Validation Framework for Artificial Intelligence in Drug Discovery. International Journal of Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/) [5] [Bahena-Culhuac et al. — Systematic benchmarking of AlphaFold and SWISS-MODEL kinase structures for structure-based drug discovery. Journal of Molecular Graphics & Modelling 2026](https://consensus.app/papers/details/4fb1d5b2257a540d94f59b60e457de9f/) [6] [Khairil et al. — AI in Drug Discovery: Clinical Failures, Regulatory Reality, and the Validation Crisis Behind the Hype. Pharmaceuticals 2026](https://consensus.app/papers/details/9c8119317b2851c4a481cb52c0d8a69/) [7] [Singh et al. — More Protein-Ligand data is needed for AlphaFold-like Models to enable drug discovery. Current Opinion in Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/) [8] [DenAdel et al. — Evaluating the role of pre-training dataset size and diversity on single-cell foundation model performance. Nature Methods 2026](https://consensus.app/papers/details/f0f6bddc16985563ad8478918950e0f4/) [9] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/) [10] [Auclair et al. — Artificial Intelligence and the Transformation of Cell and Gene Therapy Development. Pharmaceutics 2026](https://consensus.app/papers/details/44ed620e7b42599c991a36e933c3597d/) [11] [Speth et al. — Advancing cell and gene therapy: Application of AI/ML in clinical development and patient management. J Biopharmaceutical Statistics 2026](https://consensus.app/papers/details/25cc17f689cb5270bb8e2dc0a4d458f9c/) [12] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [13] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/) [14] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [15] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
Research Pulse·2026-10-06
Research Pulse — 2026-10-06
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief